Pfizer (PFE, $38.26) will receive $1.95 billion for the first 100 million doses of covid-19 vaccine
Pharmaceutical company Pfizer Inc. agreed to provide 600 million doses of its developing coronavirus vaccine to the U.S. government.
In an agreement with the U.S. Department of Health and Human Services and the Department of Defense, Pfizer, and its German partner, BioNTech BNTX, will receive $1.95 billion for the first 100 million doses of its BNT162 mRNA-based vaccine. The contract also has the potential for 500 million more doses to be made further. The vaccine is subject to regulatory approval.
Last week, Pfizer’s BNT162 vaccine candidates received 'fast track' designation by the U.S. Food and Drug Administration, based on preliminary data from Phase 1 and Phase 2 studies.
According to Tickeron, PFE's price moved above its 50-day Moving Average on July 15, 2020
This price move indicates a change in the trend, and may be a buy signal for investors. In 24 of 47 cases where PFE's price crossed above its 50-day Moving Average, its price rose further within the subsequent month. The odds of a continued Uptrend are 51%
Current price $38.30 crossed the support line at $37.37 and is trading between $38.46 resistance and $37.37 support lines. Throughout the month of 06/18/20 - 07/21/20, the price experienced a +10% Uptrend. During the week of 07/14/20 - 07/21/20, the stock enjoyed a +4% Uptrend growth.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator exceeded the 0 level on July 01, 2020. Traders may consider buying the ticker or exploring call options. In 43 of 91 cases where the ticker's Momentum Indicator exceeded 0, its price rose further within the subsequent month. The odds of a continued Uptrend are 47%.
The Moving Average Convergence Divergence (MACD) just turned positive. Considering data from situations where PFE's MACD histogram became positive, in 23 of 51 cases, the price rose further within the following month. The odds of a continued Uptrend are 45%.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 133 of 318 cases, the price rose further within the following month. The odds of a continued Uptrend are 42%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Indicator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day Moving Average crossing below its 200-day Moving Average indicates a sell signal, due to the trend repositioning lower. In 1 of 4 cases where PFE's 50-day Moving Average crossed below its 200-day Moving Average, its price fell further within the subsequent month. The odds of a continued Downtrend are 25%.
The higher Bollinger Band was broken -- a price fall is expected as the ticker heads toward the middle band, which invites the trader to consider selling or shorting the ticker, or exploring put options. In 19 of 37 cases where PFE's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued Downtrend are 51%.
The Aroon Indicator entered a Downtrend today. In 89 of 182 cases where PFE Aroon's Indicator entered a Downtrend, the price fell further within the following month. The odds of a continued Downtrend are 49%.
Fundamental Analysis (Ratings)
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 64%. During the last month, the daily ratio of advancing to declining volumes was 2.24 to 1.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.47) is normal, around the industry mean (-3.05). P/E Ratio (13.13) is within average values for comparable stocks, (215.05). Projected Growth (PEG Ratio) (0.25) is also within normal values, averaging (35.76). PFE's Dividend Yield (3.73) is considerably higher than the industry average of (0.26). P/S Ratio (3.42) is also within normal values, averaging (227.14).
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 51 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 87 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
PFE sees MACD Histogram just turned negative
PFE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on February 19, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on January 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on March 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PFE broke above its upper Bollinger Band on February 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 211 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating for company is (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.750) is normal, around the industry mean (9.384). P/E Ratio (19.574) is within average values for comparable stocks, (22.964). PFE's Projected Growth (PEG Ratio) (13.773) is very high in comparison to the industry average of (2.286). PFE's Dividend Yield (0.065) is considerably higher than the industry average of (0.025). P/S Ratio (2.430) is also within normal values, averaging (3.967).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement